Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US

被引：27
作者：
Amin, Alpesh [1 ]
Bruno, Amanda [2 ]
Trocio, Jeffrey [3 ]
Lin, Jay [4 ]
Lingohr-Smith, Melissa [4 ]
机构：
[1] Univ Calif Irvine, Irvine, CA USA
[2] Bristol Myers Squibb Co, Plainsboro, NJ USA
[3] Pfizer Inc, New York, NY USA
[4] Novosys Hlth, Green Brook, NJ USA
来源：
JOURNAL OF MEDICAL ECONOMICS | 2015年 / 18卷 / 06期
关键词：
Economic model; Healthcare costs; New oral anticoagulants; Non-valvular atrial fibrillation; Venous thromboembolism;
D O I：
10.3111/13696998.2015.1007210
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
Objective: Medical costs that may be avoided when any of the four new oral anticoagulants (NOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, are used instead of warfarin for the treatment of non-valvular atrial fibrillation (NVAF) were estimated and compared. Additionally, the overall differences in medical costs were estimated for NVAF and venous thromboembolism (VTE) patient populations combined. Methods: Medical cost differences associated with NOAC use vs warfarin or placebo among NVAF and VTE patients were estimated based on clinical event rates obtained from the published trial data. The clinical event rates were calculated as the percentage of patients with each of the clinical events during the trial periods. Univariate and multivariate sensitivity analyses were conducted for the medical-cost differences determined for NVAF patients. A hypothetical health plan population of 1 million members was used to estimate and compare the combined medical-cost differences of the NVAF and VTE populations and were projected in the years 2015-2018. Results: In a year, the medical-cost differences associated with NOAC use instead of warfarin were estimated at -$204, -$140, -$495, and -$340 per patient for dabigatran, rivaroxaban, apixaban, and edoxaban, respectively. In 2014, among the hypothetical population, the medical-cost differences were -$3.7, -$4.2, -$11.5, and -$6.6 million for NVAF and acute VTE patients treated with dabigatran, rivaroxaban, apixaban, and edoxaban, respectively. In 2014, for the combined NVAF, acute VTE, and extended VTE patient populations, medical-cost differences were -$10.0, -$10.9, -$21.0, and -$21.0 million for dabigatran, rivaroxaban, 2.5 mg apixaban, and 5mg apixaban, respectively. Medical-cost differences associated with use of NOACs were projected to steadily increase from 2014 to 2018. Conclusions: Medical costs are reduced when NOACs are used instead of warfarin/placebo for the treatment of NVAF or VTE, with apixaban being associated with the greatest reduction in medical costs.
引用
收藏
页码：399 / 409
页数：11
相关论文
共 53 条
  • [1] Miyasaka Y., Barnes M.E., Gersh B.J., Et al., Secular trends in incidence of atrial fibrillation in Olmsted County Minnesota 1980 to 2000, and implications on the projections for future prevalence, Circulation, 114, pp. 119-125, (2006)
  • [2] Go A.S., Hylek E.M., Phillips K.A., Et al., Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study, JAMA, 285, pp. 2370-2375, (2001)
  • [3] Heit J., Cohen A., Anderson F.J., Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US, Blood, 106, (2005)
  • [4] Reiffel J.A., Atrial fibrillation and stroke: Epidemiology, Am J Med, 127, pp. e15-16, (2014)
  • [5] Patel A.A., Ogden K., Veerman M., Et al., The economic burden to Medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis, Popul Health Manag, 17, pp. 159-165, (2014)
  • [6] Spyropoulos A.C., Lin J., Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: An administrative claims analysis from 30 managed care organizations, J Manag Care Pharm, 13, pp. 475-486, (2007)
  • [7] Lefebvre P., Laliberte F., Nutescu E.A., Et al., All-cause and potentially diseaserelated health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries, J Manag Care Pharm, 18, pp. 363-374, (2012)
  • [8] Kim M.H., Johnston S.S., Chu B.C., Et al., Estimation of total incremental health care costs in patients with atrial fibrillation in the United States, Circ Cardiovasc Qual Outcomes, 4, pp. 313-320, (2011)
  • [9] Goldhaber S.Z., Bounameaux H., Pulmonary embolism and deep vein thrombosis, Lancet, 379, pp. 1835-1846, (2012)
  • [10] Mahan C.E., Borrego M.E., Woersching A.L., Et al., Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates, Thromb Haemost, 108, pp. 291-302, (2012)
123456